Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Drug-induced extrapyramidal symptoms (Orphenadrine hydrochloride - Drug-induced extrapyramidal symptoms)

Records returned : 7 (on 05 Dec 2025 at 15:53:47). Return to search results for ' Drug-induced extrapyramidal symptoms '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off Label

Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

SPC

View the treatment summary for {padindicationname} on https://www.medicines.org.uk

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Orphenadrine hydrochloride

Drug:

Orphenadrine hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

Non Formulary

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

NFD1

2. Procyclidine hydrochloride

Drug:

Procyclidine hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

Blue

Formulations :

Tablets

Restrictions / Comments:

Important

PALLIATIVE CARE - Primary Care prescribing on advice from palliative care specialist team.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

3. Procyclidine hydrochloride

Drug:

Procyclidine hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

Blue

Formulations :

Tablets

Restrictions / Comments:

Important

Preferred

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Tablets are the preferred treatment option.

See PAD for additional safety advice.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

4. Procyclidine hydrochloride

Drug:

Procyclidine hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

Blue

Formulations :

Oral solution

Restrictions / Comments:

Important

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Tablets are the preferred treatment option. Reserve oral solution for patients unable to swallow the tablets.

See PAD for additional safety information.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

7. Procyclidine hydrochloride

Drug:

Procyclidine hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

See narrative

Formulations :

Injection

Restrictions / Comments:

Important

Procyclidine injection has been discontinued. There may be supplies available until mid-February 2026.
See link for details: https://www.sps.nhs.uk/shortages/discontinuation-of-procyclidine-10mg-2ml-solution-for-injection-ampoules/
Benztropine (unlicensed in the UK) may be considered as an alternative. A formulary entry for benztropine will be created once agreed for use by Surrey Heartands Acute Trusts.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

5. Trihexyphenidyl hydrochloride

Drug:

Trihexyphenidyl hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

Blue

Formulations :

Tablets

Restrictions / Comments:

Important

Procyclidine tablets are the preferred treatment option.

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Antimuscarinics should not be used in tardive dyskinesia

Recommendation for use to be made by SABP specialist only after consideration and trial of reduction of antipsychotic dose has occured or alternative treatment options have first been tried.
See PAD for additional safety advice.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

6. Trihexyphenidyl hydrochloride

Drug:

Trihexyphenidyl hydrochloride

Indication :

Drug-induced extrapyramidal symptoms

Status :

Blue

Formulations :

Oral solution

Restrictions / Comments:

Important

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Tablets are the preferred treatment option. Reserve oral solution for patients unable to swallow the tablets.

Recommendation for use to be made by SABP specialist only after consideration and trial of reduction of antipsychotic dose has occured or alternative treatment options have first been tried.

See PAD for additional safety information.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC